



**PICK UP QUICK TIPS ON...** Treating obesity like any other chronic condition and offering evidence-informed pharmacotherapy when appropriate

**Focus weight-loss conversations around patient-centered health outcomes, realistic lifestyle changes, and behavioral goal setting.**

## QUICKtip<sub>SC</sub>

**Behavioral goal setting (e.g., 30 minutes of daily walking) is often more effective than outcome-focused goal setting (e.g., losing 2 pounds each week).**

## QUICK FACTS TO CONSIDER

- 82% of individuals with obesity feel they are alone in their efforts to manage their weight.
- Health risks increase with a 0.5 or higher waist-to-height ratio (a measure of excess abdominal fat that may be a better risk indicator than BMI).
- A patient with obesity is twice as likely to have a comorbid mood disorder than patients without obesity.
- Losing 1 to 2 pounds a week is considered healthier than more rapid weight loss that may increase the risk of muscle mass loss, gall bladder and biliary disease, nutritional deficiencies, and reduced metabolism.

## CREATE A WEIGHT-FRIENDLY PRACTICE: PATIENTS NEED YOUR SUPPORT, NOT STIGMA

Focus weight loss conversations with patients on overall health and well-being. Help them overcome the myth that obesity is caused solely by a person's lack of willpower and failings to eat well or exercise. Together, identify how weight loss will personally benefit your individual patient (e.g., lowered risk of cardiovascular disease, reduced complications from diabetes, improved sleep apnea). Screen for and address factors contributing to obesity — such as medications associated with weight gain, poor sleep, and unhealthy alcohol use — during the initial visit and throughout ongoing care.

Identify current <b>MEDICATIONS</b> with increased risk of weight gain	Ask about <b>POOR SLEEP</b>	Screen for <b>UNHEALTHY ALCOHOL USE</b>
<ul style="list-style-type: none"> <li>• Talk early and often about potential weight gain related to meds – preventing and minimizing is easier than losing weight</li> <li>• Encourage patients <b>NOT</b> to give up on important prescription meds that could be causing weight gain without reaching out to you for weight management options</li> <li>• Offer patient information on prescription medications and weight gain</li> </ul> <p><b>Patient Handout</b> <a href="https://www.obesityaction.org/resources/prescription-medications-weight-gain/">https://www.obesityaction.org/resources/prescription-medications-weight-gain/</a></p>	<ul style="list-style-type: none"> <li>• Discuss the importance of healthy sleep when trying to maintain or lose weight</li> <li>• Screen for suspected obstructive sleep apnea (e.g., STOP-BANG) and other identified risks</li> <li>• Offer patient information on sleep hygiene</li> </ul> <p><b>Patient Handouts</b> Better Sleep – Better Health and Well-Being <a href="https://bit.ly/Healthy_Sleep_Habits_Adults">https://bit.ly/Healthy_Sleep_Habits_Adults</a> Healthy Sleep Habits for Children and Teens <a href="https://bit.ly/Sleep_Habits_Kids">https://bit.ly/Sleep_Habits_Kids</a></p>	<ul style="list-style-type: none"> <li>• Screen for alcohol consumption (e.g., AUDIT-C) at least annually</li> <li>• Engage patients in conversations about weight gain related to unhealthy alcohol use (e.g., increased consumption of “empty calories,” poor sleep)</li> <li>• Offer patient information about healthy lifestyle changes</li> </ul> <p><b>Patient Handouts</b> Drinking Alcohol <a href="https://bit.ly/Drinking_Alcohol">https://bit.ly/Drinking_Alcohol</a> A Healthier Liver, A Healthier You <a href="https://bit.ly/healthier_liver">https://bit.ly/healthier_liver</a></p>

**Agree on timely, realistic goals that motivate your patient to succeed. Remind them even small changes from baseline can be beneficial (e.g., reduce from 7 sodas a week to 4 rather than stopping altogether).**

# SELECT FDA-APPROVED MEDICATIONS FOR OBESITY<sup>1</sup>







FDA-approved in combination with reduced calorie diet and increased physical activity for obesity (BMI ≥ 30 kg/m<sup>2</sup>) or overweight (BMI ≥ 27 kg/m<sup>2</sup>) adults with at least one weight-related comorbid condition (hypertension, hyperlipidemia, T2DM)

**SCREEN** at baseline and ongoing for depression and suicide (PHQ-9), anxiety (GAD-7), eating disorders, pregnancy, and comorbidities. Labs include: HbA1c, lipid panel, thyroid, kidney, and liver function tests.

**PRE-SURGERY DISCONTINUATION** recommendations vary. Consult surgeon 2 weeks prior to scheduled surgery for individualized instructions.

**FOLLOW-UP QUICKLY** (within one month) after initiating therapy and slowly titrate dose or continue on same dose based on response and tolerability.

**KNOW RISKS AND BENEFITS** of all weight-loss medications. Refer to package inserts for more detail and latest package labeling: <http://dailymed.nlm.nih.gov/dailymed/>.

Class	Generic Name (Obesity Brand Name) Relative cost <sup>2</sup>	Dosage Form(s) Strengths	FDA Approved Age (years)	Mean % Weight Reduction from Baseline	Initial Weight Loss Dose	Dose Escalation Schedule	FDA Maximum Dose	Discontinuation Guidance	SELECT NON-WEIGHT LOSS BENEFITS						Comments
									T2DM	Alcohol Misuse	MACE	Hepatic	Renal	Sleep Apnea	
GLP-1 RA	<b>Tirzepatide</b> (Zepbound™) \$\$\$	Solution for SubQ injection: 2.5, 5, 7.5, 10, 12.5, 15 mg/0.5 mL single-dose pen or single-dose vial	 ≥ 18	15 – 21% at 72 weeks <sup>3</sup>	2.5 mg once weekly	After 4 weeks: 5 mg once weekly; May increase in 2.5 mg increments every 4 weeks	15 mg weekly	Discontinue at 16 weeks if < 5% weight loss from baseline (clinical consensus)	✓	¥	✓	✓ <sup>4</sup>	✓ <sup>5</sup>	✓ FDA	GI side effects may be prevalent during dose escalation and improve over time; hypotension may occur with GI side effects and dehydration; First GLP-1 to show reduced CV death; Mounjaro™ is the FDA-approved brand name for T2DM
	<b>Liraglutide</b> (Saxenda®) \$\$\$	Solution for SubQ injection: 18 mg/3 mL dial-a-dose pen (0.6, 1.2, 1.8, 2.4, 3 mg/dose)	 ≥ 12	~8% at 56 weeks on 3 mg daily	0.6 mg once daily	Increase by 0.6 mg weekly to 3 mg	3 mg daily	Discontinue at 16 weeks if < 4% weight loss from baseline	✓	¥	✓	✓ <sup>6</sup>	✓ <sup>7</sup>	¥	Victoza® is the FDA-approved brand name for T2DM and MACE
GLP-1 RA	<b>Semaglutide</b> (Wegovy®) \$\$\$	Solution for SubQ injection: 0.25, 0.5, 1 mg/0.5 mL single-dose pen; 1.7, 2.4 mg/0.75 mL single-dose pen	 ≥ 12 <sup>8</sup>	10 – 15% at 24 to 68 weeks on 2.4 mg weekly <sup>3</sup>	0.25 mg once weekly	Weeks 5 – 8: 0.5 mg; Weeks 9 – 12: 1 mg; Weeks 13 – 16: 1.7 mg; 17+ weeks: 2.4 mg	2.4 mg weekly	Discontinue at 16 weeks if < 5% weight loss from baseline	✓	✓	✓ FDA	✓ <sup>4,9</sup> FDA	✓ <sup>10</sup>	¥	Most reported adverse effects; Most FDA approvals and most studied for non-weight loss benefits in patients with T2DM; Ozempic® (injection) is the FDA-approved brand name for T2DM, MACE, and CKD; Rybelsus® (tablets) is the FDA-approved brand name for T2DM and MACE
NON-GLP-1 RA (C-IV)	<b>Phentermine</b> (Adipex-P®) <sup>11</sup> \$	Tablet, oral (scored): 37.5 mg	 ≥ 17	3 – 8% at 28 weeks <sup>12</sup>	18.75 – 37.5 mg daily <sup>13</sup>	No dose escalation	37.5 mg daily <sup>14</sup>	FDA labeling states to discontinue when tolerance to anorexiatic effect develops	—	—	—	— <sup>15</sup>	— <sup>16</sup>	—	Take Adipex-P® before breakfast or 1-2 hours after; Take Lomaira™ 30 minutes before meals; Establish baseline CV health prior to initiation (e.g., EKG, BP, HR); Contraindicated in patients with CV disease or uncontrolled hypertension; Use caution in patients with increased risk of CVD, anxiety, bipolar disorder and older adults; May have trouble sleeping for first 2-3 nights after initiation or dose increase
	<b>Phentermine</b> (Lomaira™) \$	Tablet, oral: 8 mg							—	—	—	—	—		
	<b>Phentermine/Topiramate</b> (Qsymia®) \$\$	ER capsule, oral: 3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg, 15 mg/92 mg	 ≥ 12	7.8 – 10.9% at 56 weeks	3.75 mg/23 mg every morning with or without food	After 14 days: 7.5 mg/46 mg; If < 3% weight loss from baseline (adults) or < 3% BMI reduction (pediatrics) after 12 weeks on 7.5 mg/46 mg; 11.25 mg/69 mg for 14 days then increase to 15 mg/92 mg	15 mg/92 mg daily	Gradually taper to reduce seizure risk at 12 weeks on maximum dose if < 5% weight loss from baseline (adults) or < 5% BMI reduction (pediatrics)	+ <sup>17</sup>	— <sup>18</sup>	—	— <sup>15</sup>	— <sup>19</sup>	—	Side effects may limit use; Contraindicated in pregnancy; See comments for phentermine; Gradually taper over at least 1 week when at max dose to avoid withdrawal and prevent seizures
NON-GLP-1 RA	<b>Naltrexone/Bupropion</b> (Contrave®) \$\$	ER tablet, oral: 8 mg/90 mg	 ≥ 18	5.4 – 8.1% at 56 weeks on 32/360 mg daily <sup>20</sup>	8 mg/90 mg (1 tab) in the morning	Week 2: 1 tab in the morning, and evening Week 3: 2 tabs in the morning, 1 tab in the evening Week 4+ : 2 tabs in the morning and evening	32 mg/360 mg total daily dose	Discontinue at 12 weeks on maintenance dose if < 5% of weight loss from baseline	+ <sup>17</sup>	— <sup>21</sup>	—	—	— <sup>22</sup>	—	Side effects may limit use; Be aware of contraindications including patients with seizure disorder (dose-related risk with bupropion) and patients taking opioids (naltrexone is opioid antagonist); Avoid taking with high fat meals to reduce seizure risk; Avoid use in patients at risk of abruptly stopping alcohol (seizure risk with bupropion); False-positive urine drug screens for amphetamines possible

1. Orlistat not listed due to side effects and low relative efficacy; Phentermine monotherapy approved for obesity as adjunct to exercise, behavioral modification, and caloric restriction.  
 2. Relative cost from lowest (\$) to higher (\$\$\$) based on GoodRx pricing. 3. More weight loss observed with higher doses. 4. Improved liver enzymes, reduction in liver fat, increased rates of MASH resolution (MASH the more definitive new term for NASH), and liver fibrosis improvement. 5. Improvement in renal biomarkers in short-term substudies. 6. Reduction in liver fat and increased rates of NASH resolution (NASH the less definitive term replaced by MASH); mixed results on liver fibrosis improvement. 7. Reductions in macroalbuminuria and slower eGFR decline in patients with T2DM. 8. Pediatric patients ≥ 12 with baseline BMI ≥ 95 percentile for age and weight. 9. Conditional FDA approval for noncirrhotic MASH with F2 – F3 fibrosis in adults.  
 10. Reduced risk of sustained eGFR decline, end stage kidney disease, and CV disease in patients with T2DM and CKD. 11. FDA-approved generics available. 12. 4% to 19% mean body weight loss seen in chart reviews of patients taking 60 - 112 mg daily. 13. Maximum dose (30 or 37.5 mg) may be given once daily or in divided doses depending on patient needs. 14. FDA usual dose. 15. It is unclear whether observed hepatic benefits are the direct result of phentermine, med-associated weight loss, or a combination of the two 16. Maximum daily dose in severe impairment is 15 mg; avoid use in ESRD. 17. Reduced HbA1c. 18. Benefit shown with topiramate monotherapy. 19. Maximum daily dose in severe impairment is 7.5/46 mg; avoid use in ESRD. 20. More weight loss with behavioral program. 21. Benefit shown with naltrexone monotherapy at higher dose. 22. Moderate to severe renal impairment: 1 tablet twice daily; avoid in ESRD.

**KEY:** ✓ Clinical benefit favorable with T2DM dosing; + Clinical benefit potentially favorable; FDA FDA approved use/benefit for obesity brand name; ¥ Potential class effect; no high-quality studies identified for this indication; — ≤ 2 studies on benefits identified

**BMI** Body Mass Index; **BP** Blood Pressure; **CKD** Chronic Kidney Disease; **CV** Cardiovascular; **CVD** Cardiovascular Disease; **eGFR** Estimated Glomerular Filtration Rate; **EKG** Echocardiogram; **ER** Extended-Release; **ESRD** End-Stage Renal Disease; **F2 – F3 (fibrosis)** Moderate to Advanced Liver Fibrosis; **FDA** Food and Drug Administration; **GAD-7** Generalized Anxiety Disorder-7-item Screening Tool; **GI** Gastrointestinal; **GIP** Gastric Inhibitory Polypeptide; **GLP-1 RA** Glucagon-like Peptide Receptor Agonist; **HbA1c** Glycated Hemoglobin; **HR** Heart Rate; **MACE** Major Cardiovascular Events; **MASLD** Metabolic Dysfunction-Associated Steatotic Liver Disease; **MASH** Metabolic Dysfunction-Associated Steatohepatitis; **NASH** Non-Alcoholic Steatohepatitis; **PHQ-9** Patient Health Questionnaire-9; **SUBQ** Subcutaneous; **T2DM** Type 2 Diabetes Mellitus

# TIPS FOR PATIENTS TAKING DUAL GIP/GLP-1 OR GLP-1 RAs

Help patients meet behavioral goals (e.g., nutritious, reduced calorie diet, increased physical activity, improved sleep) that can and should continue after med changes or discontinuation. Remind patients that meds are just a part of an overall wellness plan.



## MINIMIZE MUSCLE MASS LOSS AND MUSCLE WASTING

- Lose weight gradually rather than rapid reductions (no more than 1 to 2 pounds per week)
- Aim for protein intake of at least 0.8 - 1.2 grams/day/kg of body weight
- Eat protein first during meals and snacks
- Add resistance and strength training exercises 3 times per week



## GET AHEAD OF GASTROINTESTINAL SIDE EFFECTS

- Titrate meds slowly
- Eat small, frequent meals
- Stay hydrated (at least 64 oz of water or sugar-free beverages per day)
- Increase daily fiber intake along with good hydration to reduce constipation and stabilize blood sugar
- Consider short-term use of proton pump inhibitor or H2-blocker for heartburn



## MONITOR MEDICATIONS, VITAMINS, AND MINERALS THAT MAY BE IMPACTED BY DELAYED GASTRIC EMPTYING

- Adjust narrow therapeutic index medications (e.g., warfarin, levothyroxine) as needed
- Discuss risk of reduced effectiveness of oral contraceptives and consider adding a second form of birth control
- Consider offering vitamin and mineral supplementation when needed



## DISCUSS RISKS OF OTHER SIDE EFFECTS

- Increased risk of gall bladder and biliary diseases – *Increased risk may be associated with higher doses, longer duration, and when prescribed for weight loss*
- Rare but serious ocular risks – *Patient should receive an in-person, comprehensive, dilated ocular fundus exam at baseline and annually*
- Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2

Tracking tools help you follow and support patient progress and long-term lifestyle changes.

## REFERENCE LIST

- American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024;47(Suppl 1):S145-S157. doi:10.2337/dc24-3008
- American Optometric Association. Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) and Ocular Health: Guidance for Ophthalmic Practice. [https://www.aoa.org/AOA/Documents/Practice%20Management/Clinical%20Guidelines/PAOA%20GLP-1\\_EBO\\_Clinical-report.pdf](https://www.aoa.org/AOA/Documents/Practice%20Management/Clinical%20Guidelines/PAOA%20GLP-1_EBO_Clinical-report.pdf). Published 2025. Accessed October 1, 2025.
- Appelroo EM, Tuttle KR, Pavo I, et al. Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-3 Clinical Trials. *Diabetes Care*. 2025;48(3):430-436. doi:10.2337/dc24-1773
- Bardóczi A, Matics ZZ, Turan C, et al. Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials. *Sleep Med Rev*. 2025;82:102119. doi:10.1016/j.smrv.2025.102119
- Bays HE, Lazarus E, Primack C, Fitch A. Obesity pillars roundtable: Phentermine - Past, present, and future. *Obes Pillars*. 2022;3:100024. Published 2022 Jun 28. doi:10.1016/j.obpill.2022.100024
- Better Health Channel. Alcohol and Weight Gain. <https://www.betterhealth.vic.gov.au/health/healthy/living/Alcohol-and-weight-gain>. Accessed October 30, 2025.
- Blackman A, Foster GD, Zarnmit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. *Int J Obes (Lond)*. 2016;40(8):1310-1319. doi:10.1038/sj.ijo.2016.052
- Centers for Disease Control and Prevention. New CDC Data Show Adult Obesity Prevalence Remains High. [www.cdc.gov/media/releases/2024/p0912-adult-obesity.html](https://www.cdc.gov/media/releases/2024/p0912-adult-obesity.html). Accessed October 30, 2025.
- Centers for Disease Control and Prevention. Steps for Losing Weight. <https://www.cdc.gov/healthy-weight/growth/losing-weight/index.html>. Accessed October 30, 2025.
- Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. *Nat Med*. 2024;30(7):2058-2066. doi:10.1038/s41591-024-03015-5
- Cornier MA. A review of current guidelines for the treatment of obesity. *Am J Manag Care*. 2022;28(15 Suppl):S288-S296. doi:10.37765/ajmc.2022.89292
- Frias Z, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTÉ): a double-blind, randomised, phase 3B trial. *Lancet Diabetes Endocrinol*. 2021;9(9):563-574. doi:10.1016/S2213-8587(21)00174-1
- Gadalla TM. Association of obesity with mood and anxiety disorders in the adult general population. *Chronic Dis Can*. 2009;30(1):29-36.
- Garvey WT, Mechanick JL, Brett EM, et al. American Association of Clinical Endocrinologists And American College of Endocrinology. Comprehensive Clinical Practice Guidelines for Medical Care Of Patients With Obesity. *Endocr Pract*. 2016;22 Suppl 3:1-203. doi:10.4158/EP161366.GL
- Grunwald E, Shah R, Hernandez R, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. *Gastroenterology*. 2022;162(5):1198-1225. doi:10.1053/j.gastro.2022.08.045
- Healthline. Is It Best to Lose Weight Too Quickly? <https://www.healthline.com/nutrition/losing-weight-too-fast>. Accessed October 30, 2025.
- He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *JAMA Intern Med*. 2022;182(5):513-519. doi:10.1001/jamainternmed.2022.0358
- Hendershot CS, Bremner MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2025;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789
- Jensen MD, Ryan DH, Apovian CM, et al. 2015 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 2014;129(25 Suppl 2):S102-S138. doi:10.1161/01.cir.0000047175.978233.2
- Jerlbag E. GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder. *Endocrinology*. 2025;166(4):bqaf028. doi:10.1210/endo/bqaf028
- Kaiser Permanente. Weight management Screening and Intervention Guidelines. <https://www.provider.kaiserpermanente.org/static/pdf/provider/guidelines/weight.pdf>. Published 2022. Accessed October 30, 2025.
- Kaplan LM, Golden A, Jinnett K, et al. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. *Obesity (Silver Spring)*. 2018;26(1):61-69. doi:10.1002/oby.22054
- Kindel TL, Wang AY, Wadwa A, et al. Multi-site clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. *Surg Endosc*. 2025;39(1):180-183. doi:10.1007/s00464-024-11263-2
- Kamrul-Hasan A, Patra S, Dutta D, et al. Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis. *World J Diabetes*. 2025;16(2):101282. doi:10.4239/wjv.16.2.101282
- Lähteenaho M, Tiihonen J, Solismaa A, Tanskanen A, Mitterdorfer-Rutz E, Taipale H. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. *JAMA Psychiatry*. 2025;82(1):94-98. doi:10.1001/jamapsychiatry.2024.3599
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med*. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2207563
- Locke EA, Latham GP. Building a practically useful theory of goal setting and task motivation. A 35-year odyssey. *Am Psychol*. 2002;57(9):705-717. doi:10.1037/0003-066x.57.9.705
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. *N Engl J Med*. 2024;391(4):299-310. doi:10.1056/NEJMoa2401943
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *N Engl J Med*. 2024;391(15):1193-1205. doi:10.1056/NEJMoa2404881
- Manton E. Alcohol and obesity: A systematic review scoping study. *FARE*. 2013. <https://fare.org/wp-content/uploads/Manton-2013-Alcohol-and-Obesity.pdf>. Accessed October 30, 2025.
- Mayer SB, Graybill S, Raffa SD, et al. Synopsis of the 2020 U.S. VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity. *Mil Med*. 2021;186(9-10):884-896. doi:10.1093/milmed/usab114
- NICE. Overweight and Obesity Management: Overview. *NICE Guideline NG246*. Published 2025. <https://www.nice.org.uk/guidance/ng246>. Accessed February 28, 2025.
- Obesity Action Coalition. Prescription Medications and Weight Gain. <https://www.obesityaction.org/resources/prescription-medications-weight-gain/>. Accessed October 30, 2025.
- Ogawa W, Hirota Y, Miyazaki S, et al. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. *Endocr J*. 2024;71(3):225-231. doi:10.1507/endorc.EJ25-0593
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027
- Park SJ, Ha Y, Lee JH, Lee KS, Chon YE. Comparison of effectiveness between phentermine/topiramate and liraglutide in obese patients with nonalcoholic fatty liver disease. *Research Square*. Posted April 10, 2024. doi:10.21203/rs.3.rs-4183955/v1
- Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. *CMAJ*. 2025;197(27):E797-E809. Published 2025 Aug 10. doi:10.1503/cmaj.250502
- Pérez-Cruz E, Guevara-Cruz M, Ortiz-Gutiérrez S, Luna-Camacho Y, Guzmán-Aguilar R, Briceno-Sáenz G, et al. Effect of phentermine on hepatic steatosis in bariatric surgery: a pilot study. *Med Princ Pract*. 2022;31:254-261. doi:10.1159/000524805
- Petkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med*. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347
- Petersen R, Pan L, Blanck HM. Racial and Ethnic Disparities in Adult Obesity in the United States: CDC's Tracking to Inform State and Local Action. *Prev Chronic Dis*. 2019;16:180579. DOI: <https://dx.doi.org/10.5888/pcd16.180579>
- Pharmacist letter. Comparison of GLP-1 GIP/GLP-1 Receptor Agonists. <https://pharmacist.pharmacistresearch.com/Content/Segments/PRL/2017/Jan/Comparison-of-GLP-1-and-GIP-GLP-1-Receptor-Agonists-10594>. Accessed October 30, 2025.
- Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet*. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6
- Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. *N Engl J Med*. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258
- Shariha RZ, Shikora S, White KP, Macedo G, Touli J, Kow L. Summarizing Consensus Guidelines on Obesity Management: A Joint, Multidisciplinary Venture of the International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO) and World Gastroenterology Organisation (WGO). *J Clin Gastroenterol*. 2023;57(10):967-976. doi:10.1097/MCG.0000000000001916
- Therapeutic Research Center. Keep Potential Eye Risks With GLP-1 Agonists in Sight. *Pharmacist's Letter*. 2025; <https://trchealthcare.com/insights-newsletter-august-2025-emerging-trends-for-clinical-leadership/#:~:text=Keep%20Potential%20Eye%20Risks%20With,or%20>
- the%20superiority%20of%20injections. Accessed October 30, 2025.
- Traversy G, Chaput JP. Alcohol Consumption and Obesity: An Update. *Curr Obes Rep*. 2015;4(1):122-130. doi:10.1007/s13679-014-0129-4
- World Gastroenterology Organisation (WGO). IFSO-WGO guidelines on obesity. WGO. 2022. <https://www.worldgastroenterology.org/UserFiles/file/guidelines/obesity-english-2022.pdf>
- Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. *Postgrad Med J*. 2022;134(1):14-19. doi:10.1093/pgmj/ckab281.2021.2002616
- Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. *CMAJ*. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707
- University of Vermont. Vermont Academic Detailing Program. Management of Obesity. <https://www.med.uvm.edu/ahcc/vermontacademicdetailing>. Accessed October 30, 2025.
- US Department of Veterans Affairs. Veterans Health Administration PBM Academic Detailing Service. Weight Management A VA clinicians Summary. [https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/508/1B10-1784\\_WeightMgmt-ClinicianSummary-P97235.pdf](https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/508/1B10-1784_WeightMgmt-ClinicianSummary-P97235.pdf). Published 2025. Accessed October 30, 2025.
- US Preventive Services Task Force, Curry SJ, Krist AH, et al. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018;320(11):1163-1171. doi:10.1001/jama.2018.13022
- US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, et al. Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care: The SUMMIT randomized clinical trial. *JAMA Intern Med*. 2017 Oct 11;177(10):1480-1488. doi:10.1001/jamainternmed.2017.3947
- Yoo EG. Waist-to-height ratio as a screening tool for obesity and cardiometabolic risk. *Korean J Pediatr*. 2016 Nov;59(11):425-431. doi:10.3345/kjp.2016.59.11.425. Epub 2016 Nov 18. PMID: 27895689. PMCID: PMC5118501
- Zheng YJ, Soegiharto C, Au HCT, et al. A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder. *Acta Neuropsychiatr*. 2025;37:e51. Published 2025 Feb 19. doi:10.1017/neu.2025.6
- Product labeling and FDA approval references available upon request.

## WRITING GROUP

Writing Group (and Disclosures for Pharmaceutical Relationships): Sarah Ball, PharmD (none), Kelly Barth, DO (none), Sandra Counts, PharmD (none), Nancy Hahn, PharmD (none), Jamie Hansen, PharmD (none), Lauren Linder Wier, PharmD (none), Jenna McCauley, PhD (none), Megan Pruitt, PharmD (none), Talisha Payne Ratliff, PharmD (none), Sophie Robert, PharmD (none), Christine San Giovanni, MD (none), Chris Wisniewski, PharmD (none). Acknowledgements: Dr. Kathryn Anderson and Dr. Susan Evenhouse provided clinical input and support. Chloe Bays assisted with concept design and review. The MUSC Drug Information Center assisted with background research. Call 843.792.3896 or email druginfo@musc.edu for free access to MUSC's Drug Information Center to answer provider-specific questions and requests from materials delivered.

The information contained in this summary is intended to assist primary care providers in the management of obesity in non-pregnant adults in a primary care setting. This advice contains general recommendations and is advisory only. It is not intended to replace sound clinical judgment, nor should it be regarded as a substitute for individualized diagnosis, treatment, management, or overall care based on an individual patient's clinical conditions.